Osteoarthritis treatment and device
A method for treating arthritis of a joint includes identifying a bone lesion in a bone adjacent to the joint; and implanting in the bone a reinforcing member in or adjacent to the bone lesion. A kit for conducting the method includes: (a) at least one reinforcing member having a proximal face adapted to face the joint, a distal face adapted to face away from the joint, and a wedge-shaped edge adapted to pierce bone, wherein the at least one reinforcing member is planar and sterile; and (b) a container adapted to maintain the at least one reinforcing member sterile. Another kit includes: (a) a sterile fluid; (b) a syringe for injecting the fluid into a bone; (c) a curing agent adapted to cure the fluid to polymerize and/or cross-link; and (d) a container adapted to maintain the sterility of contents of the container.
1. A method of injecting an injectable fluid material into a targeted treatment area in a subchondral region of a first bone adjacent a joint of a patient for treating a bone marrow lesion identified in the subchondral region, the method comprising:
identifying a bone marrow lesion (BML) in a subchondral region of a first bone adjacent a joint of a patient, the subchondral region of the first bone occurring under an articular surface of the first bone;
creating, in the first bone that contains the bone marrow lesion in the subchondral region, a subchondral injection path to a targeted treatment area for injecting an injectable fluid material into the targeted treatment area, wherein said creating is conducted without creating a void in the targeted treatment area that opens into the overlying articular cartilage of the first bone adjacent the joint so as to preserve an existing condition of the overlying articular cartilage of the first bone adjacent the joint; and
injecting an injectable fluid material into the targeted treatment area via the subchondral injection path, wherein the injectable fluid material is resorbable and osteoconductive in the targeted treatment area for supporting new bone growth in the targeted treatment area, and wherein the injectable fluid material is left in the targeted treatment area without also delivering and leaving a solid structural implant in the targeted treatment area in addition to the injectable fluid material, the injectable fluid material comprising a calcium phosphate and hyaluronic acid,
where said injecting introduces at least some of the injectable fluid material into defective bone that remains in the identified bone marrow lesion following said creating,
wherein said identifying includes identifying the bone marrow lesion through use of magnetic resonance imaging (MRI) of the joint or a Technetium-99 bone scan of the joint.
2. The method of claim 1 , wherein the bone marrow lesion is less than 10 cm from the joint.
3. The method of claim 1 , wherein the bone marrow lesion is less than 5 cm from the joint.
4. The method of claim 1 , wherein the bone marrow lesion is less than 1 cm from the joint.
5. The method of claim 1 , wherein the bone marrow lesion is identified through use of magnetic resonance imaging (MRI) of the joint.
6. The method of claim 5 , wherein said identifying includes viewing the bone marrow lesion on an MRI of the joint.
7. The method of claim 1 , wherein the joint is a knee joint.
8. The method of claim 1 , wherein the bone marrow lesion is in a proximal tibia.
9. The method of claim 1 , wherein the bone marrow lesion is in a distal femur.
10. The method of claim 1 , wherein the joint is other than a knee joint.
11. The method of claim 1 , wherein said injecting includes use of a syringe.
12. The method of claim 11 , wherein the syringe includes a needle.